Page last updated: 2024-11-06

mibefradil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mibefradil is a calcium channel blocker that was developed for the treatment of hypertension and angina. It is a potent inhibitor of the L-type calcium channel, which is involved in the regulation of heart rate and blood pressure. Mibefradil was withdrawn from the market in 1998 due to its potential for serious drug interactions, particularly with the cytochrome P450 enzyme system. The drug was studied extensively for its potential therapeutic benefits, but its clinical use was limited by its safety profile. Research on mibefradil has helped to advance our understanding of calcium channel blockers and their role in cardiovascular disease. Its synthesis involves a multi-step process that includes the use of various organic reactions. Mibefradil is a chiral molecule, and its enantiomers have different pharmacological effects. The drug was also investigated for its potential anti-inflammatory and neuroprotective properties.'

Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60663
CHEMBL ID45816
CHEBI ID6920
SCHEMBL ID39551
MeSH IDM0167272

Synonyms (67)

Synonym
BRD-K09549677-300-01-8
(1s,2s)-2-(2-{[3-(1h-benzimidazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(1-methylethyl)-1,2,3,4-tetrahydronaphthalen-2-yl (methyloxy)acetate
NCGC00015683-01
lopac-m-5441
LOPAC0_000748
mibefradil
C07222
116644-53-2
DB01388
NCGC00161420-01
smr000326970
mibefradil dihydrochloride hydrate
MLS001056800 ,
acetic acid, methoxy-, 2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, (1s-cis)-
2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate (1s-cis)-
(1s-cis)-2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate
mibefradil [inn:ban]
NCGC00161420-03
[(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1h-naphthalen-2-yl] 2-methoxyacetate
ro 40 5967
ro-405967-001
(1s,2s)-(2-((3-(2-benzimidazolyl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate
gtpl2522
ro 405967
NCGC00161420-04
(1s,2s)-2-(2-((3-(1h-benzo[d]imidazol-2-yl)propyl)(methyl)amino)ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
2-{2-[3-(1h-benzoimidazol-2-yl)-propylamino]-ethyl}-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester(mibefradil)methoxy-acetic acid
methoxy-acetic acid 2-(2-{[3-(1h-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester
bdbm50117922
methoxy-acetic acid (1s,2s)-2-(2-{[3-(1h-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester
CHEMBL45816 ,
chebi:6920 ,
AC1L1TOE ,
D08217
mibefradil (inn)
CCG-204833
27b90x776a ,
unii-27b90x776a
HY-15553
CS-1218
mibefradil [mi]
mibefradil [vandf]
mibefradil [who-dd]
mibefradil [inn]
AKOS022185482
SCHEMBL39551
[(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoranyl-1-propan-2-yl-3,4-dihydro-1h-naphthalen-2-yl] 2-methoxyethanoate;hydrate;hydrochloride
2-methoxyacetic acid [(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoro-1-isopropyl-tetralin-2-yl] ester;hydrate;hydrochloride
bdbm78934
cid_16746591
2-methoxyacetic acid [(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1h-naphthalen-2-yl] ester;hydrate;hydrochloride
[(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1h-naphthalen-2-yl] 2-methoxyacetate;hydrate;hydrochloride
(1s,2s)-2-[2-{[3-(1h-benzimidazol-2-yl)propyl]methylamino}ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
(1s,2s)-2-[2-{[3-(1h-benzimidazol-2-yl)propyl]-methylamino }ethyl]-6-fluoro- 1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
(1s,2s)-2-[2-{[3-(1h-benzimidazol-2-yl)propyl]-methylamino}ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
acetic acid, methoxy-, (1s,2s)-2-[2-[[3-(1h-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester
[(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoro-1-isopropyl-tetralin-2-yl] 2-methoxyacetate
DTXSID1023318
ro40-5967
BCP09875
Q6827783
(1s,2s)-2-(2-{[3-(1h-benzimidazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(propan-2-yl)-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
SDCCGSBI-0050726.P002
NCGC00161420-12
nsc760798
nsc-760798
mibefradildihydrochloride

Research Excerpts

Overview

Mibefradil (Ro 40-5967) is a novel calcium antagonist from a new chemical class and is the first that selectively blocks the T-type calcium channel. It is a potent cell surface blocker of Orai channels, demonstrating a new pharmacological action of this compound.

ExcerptReferenceRelevance
"Mibefradil is a tetralol derivative chemically distinct from other calcium channel antagonists. "( Mibefradil block of cloned T-type calcium channels.
Cribbs, LL; Hanck, DA; Lee, JH; Martin, RL; Perez-Reyes, E, 2000
)
3.19
"Mibefradil, which acts as a T-type calcium channel blocker, exerts beneficial effects in patients with heart failure."( Mibefradil Alleviates High-Glucose-induced Cardiac Hypertrophy by Inhibiting PI3K/Akt/mTOR-mediated Autophagy.
Chen, B; Dai, Y; Deng, JL; Guo, SD; Li, PL; Shan, MY; Xu, ZH; Zhang, KB; Zhao, LG, 2020
)
2.72
"Mibefradil is a potent cell surface blocker of Orai channels, demonstrating a new pharmacological action of this compound in regulating cell growth and death, which could be relevant to its anti-cancer activity."( Mibefradil, a T-type Ca
Chen, GL; Hallett, T; Li, P; Rubaiy, HN; Saurabh, R; Xu, SZ; Zaibi, N; Zeng, B, 2019
)
3.4
"Mibefradil is a Ca2+ channel antagonist that inhibits both T-type and high-voltage-activated Ca2+ channels. "( NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels.
Hansen, JB; Huang, L; Keyser, BM; Li, M; Ragsdale, DS; Tagmose, TM; Taylor, JT; Zhang, M; Zhuang, H, 2004
)
1.77
"Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels. "( State-dependent mibefradil block of Na+ channels.
Hanck, DA; McNulty, MM, 2004
)
2.11
"Mibefradil is a tetralol derivative once marketed to treat hyper-tension. "( An inner pore residue (Asn406) in the Nav1.5 channel controls slow inactivation and enhances mibefradil block to T-type Ca2+ channel levels.
Hanck, DA; Kyle, JW; Lipkind, GM; McNulty, MM, 2006
)
2
"Mibefradil (Ro 40-5967) is a novel calcium antagonist from a new chemical class and is the first that selectively blocks the T-type calcium channel. "( Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
Bakx, AL; Braun, S; Bruschke, AV; Emanuelsson, H; Kobrin, I; van der Wall, EE, 1995
)
2
"Mibefradil is a novel calcium antagonist that is selective for the T-type voltage-operated calcium channel rather than the L type. "( Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel.
Bühler, FR; Clozel, JP; Iberg, N; Schmitt, R, 1995
)
3.18
"Mibefradil is a novel calcium channel antagonist that shows a high bioavailability, induces no reflex tachycardia and has no negative inotropic effects."( Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
Braun, S; Emanuelsson, H; Kobrin, I; van der Wall, EE, 1996
)
2.01
"Mibefradil is a new, safe, well tolerated and very effective dose-dependent anti-ischemic calcium channel antagonist."( Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
Braun, S; Emanuelsson, H; Kobrin, I; van der Wall, EE, 1996
)
2.01
"Mibefradil is a new calcium antagonist that can inhibit cardiac calcium current without reducing myocardial force development."( The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation.
Billman, GE; Hamlin, RL, 1996
)
1.37
"Mibefradil is a new, selective T-type and L-type calcium channel blocking agent. "( Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction.
Ahn, S; Benedict, CR; Chapelle, F; Hayashida, W; Hess, OM; Kobrin, I; Pouleur, H; Rousseau, MF; van Eyll, C, 1996
)
1.95
"Mibefradil (Ro40-5967) is a chemically novel non-dihydropyridine calcium antagonist. "( Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
Crome, R; Elliott, HL; Glen, SK; MacMahon, M; Meredith, PA; Petrie, JR; Reid, JL, 1995
)
1.98
"Mibefradil is a well-tolerated and efficacious antihypertensive agent well suited to single daily dosing because of its intrinsic long plasma half-life. "( Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
Crome, R; Elliott, HL; Glen, SK; MacMahon, M; Meredith, PA; Petrie, JR; Reid, JL, 1995
)
1.98
"Mibefradil is a novel calcium antagonist belonging to a new chemical class of benzimidazolyl-substituted tetraline derivatives. "( Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
Bernink, PJ; Braun, S; Kobrin, I; van der Vring, JA; van der Wall, EE; van Velhuisen, DJ,
)
1.88
"Mibefradil is a calcium channel blocker that selectively blocks T channels and displays moderately negative inotropic properties only at high doses."( Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
Clozel, JP; Compagnon, P; Henry, JP; Koen, R; Lallemand, F; Macé, B; Mulder, P; Richard, V; Thuillez, C, 1997
)
1.27
"Mibefradil is a novel calcium antagonist that blocks selectively the T-type calcium channels. "( The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
Archambault, F; Dalle Ave, S; Lacourcière, Y; Lefebvre, J; Lindberg, E; Poirier, L; Ward, C, 1997
)
1.98
"Mibefradil is a member of new class of agents that, due to its unique mechanism of action and pharmacologic and physiologic profile, may offer a significant advance in the treatment of heart failure. "( The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil).
Levine, TB, 1997
)
1.97
"Mibefradil (Ro 40-5967) is a novel nondihydropyridine calcium antagonist. "( Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil.
Böhm, M; Cremers, B; Flesch, M; Südkamp, M, 1997
)
1.99
"Mibefradil is a recently introduced calcium antagonist that, as a tetralol derivative, is chemically distinct from previous calcium antagonists. "( Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist.
Abernethy, DR, 1997
)
2
"Mibefradil is a new benzimidazolyl-substituted tetraline-derivative calcium antagonist. "( Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial.
Braat, S; Kadr, H; Kobrin, I; Ramires, JA; Rutsch, W; Tzivoni, D, 1997
)
2.12
"Mibefradil is a new calcium antagonist with promising pharmacological and clinical properties."( Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
Lüscher, TF; Noll, G, 1998
)
1.02
"Mibefradil is a new calcium antagonist with a novel mechanism of action since it is the only drug available so far able to block T channels."( Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension.
Waeber, B, 1998
)
1.29
"Mibefradil is a new, selective T-channel calcium antagonist which has no relevant effects on cardiac contractility, sympathetic activity or neurohormonal levels."( Different effects of calcium antagonists in a rat model of heart failure.
Mulder, P; Richard, V; Thuillez, C, 1998
)
1.02
"Mibefradil is a recently characterized calcium antagonist and the first that is selective for T-type calcium channels."( The physiological and pharmacological significance of cardiovascular T-type, voltage-gated calcium channels.
Triggle, DJ, 1998
)
1.02
"Mibefradil is a recently developed calcium antagonist with a unique chemical structure, pharmacologic profile, and mode of action."( Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
Massie, BM, 1998
)
2.46
"Mibefradil is a T-type and L-type calcium channel blocker (CCB) released in the United States in 1997 for management of hypertension and chronic stable angina. "( Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers.
Horowitz, BZ; Linden, DH; Mullins, ME; Norton, RL; Smith, GW; Stump, J, 1998
)
2.03
"Mibefradil is a new T-channel selective calcium antagonist effective in the treatment of hypertension and chronic stable angina pectoris. "( Mibefradil pharmacokinetic and pharmacodynamic population analysis.
Banken, L; Welker, HA, 1998
)
3.19
"Mibefradil is a new calcium channel antagonist (CCA) that acts on both L- and T-type channels, with 10-fold selectivity for T-type channels. "( Antioxidant and cytoprotective activities of the calcium channel blocker mibefradil.
Mak, IT; Mason, PE; Mason, RP; Tulenko, TN; Walter, MF, 1998
)
1.97
"Mibefradil is a CCA featuring a selective blockade of T-type Ca2(+)-channels."( Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats.
Chung, O; Daemen, MJ; Illner, S; Jänichen, G; Rossius, B; Sandmann, S; Spitznagel, H; Unger, T; Xia, QG, 1998
)
1.29
"Mibefradil is a single-enantiomer calcium antagonist belonging to a new class, the tetralol derivatives. "( Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
Welker, HA, 1998
)
2.04
"Mibefradil is a calcium antagonist approved for the treatment of hypertension and chronic stable angina pectoris. "( Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
Pordy, R; Woittiez, A, 1998
)
2.04
"Mibefradil is a novel calcium channel antagonist that selectively blocks T-channels. "( Antioxidative action of the novel calcium channel antagonist mibefradil on low-density lipoproteins.
Lange, M; Leonhardt, W, 1998
)
1.98
"Mibefradil is a new cardiovascular drug with peculiar Ca++ antagonistic properties. "( Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells.
Capponi, AM; Ertel, EA; Rossier, MF; Vallotton, MB, 1998
)
2.06
"Mibefradil is a calcium antagonist with few negative inotropic effects at therapeutic concentrations."( Unique cardioprotective action of the new calcium antagonist mibefradil.
Backenköhler, U; Dörge, H; Heusch, G; Jalowy, A; Post, H; Schulz, R; Vahlhaus, C, 1999
)
1.99
"Mibefradil is an effective but well-tolerated antihypertensive that also lowers heart rate over 24 h in OSA, in conditions known to increase BP."( Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea.
Grote, L; Heitmann, J; Hinder, M; Knaack, L; Köhler, U; Peter, JH,
)
1.87
"Mibefradil is a novel calcium channel blocker with activity at both L-type and T-type calcium channels. "( Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism.
Baxter, GF; Gadgil, S; Mocanu, MM; Yellon, DM, 1999
)
3.19
"Mibefradil is a selective T-type Ca(2+) channel blocker that exerts a potent vasodilating but weak inotropic action. "( Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction.
Meissner, A; Min, JY; Sandmann, S; Simon, R; Unger, T, 1999
)
2.05
"Mibefradil is a novel Ca(2+) channel antagonist that preferentially blocks T-type Ca(2+) channels in many cells. "( Mibefradil potently blocks ATP-activated K(+) channels in adrenal cells.
Enyeart, JA; Enyeart, JJ; Gomora, JC, 1999
)
3.19
"Mibefradil is a novel Ca(2+) antagonist which blocks both high-voltage activated and low voltage-activated Ca(2+) channels. "( High affinity interaction of mibefradil with voltage-gated calcium and sodium channels.
Berjukov, S; Eller, P; Hering, S; Huber, I; Kimball, SD; Knaus, HG; Striessnig, J; Toth, G; Wanner, S, 2000
)
2.04
"Mibefradil is a tetralol derivative that inhibits cloned and native T-type voltage-operated calcium channels (VOCCs) at an IC50 of 1 microM and with an apparent 15-fold selectivity for T- over L-type VOCCs. "( Evidence against an action of mibefradil at N-type voltage-operated calcium channels.
Angus, JA; Xi, Q, 2001
)
2.04
"Mibefradil is a T-type calcium-channel antagonist and arterial vasodilator with negative chronotropic effects. "( Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial.
Dean, DM; Gervais, PB; Goodman, S; Langer, A; Lee, DS; Lenis, J; Ma, P, 2002
)
1.76

Effects

Mibefradil has been repurposed from an abandoned antihypertensive to a targeted solid tumor treatment. It has antiischemic properties resulting from dilation of coronary and peripheral vascular smooth muscle, and a slight reduction in heart rate.

ExcerptReferenceRelevance
"Mibefradil has a higher affinity for T-type over L-type Ca2+ channels, and the drug has been used in the gastrointestinal tract to identify T-type currents."( Effect of mibefradil on sodium and calcium currents.
Bernard, CE; Farrugia, G; Gibbons, SJ; Ou, Y; Strege, PR, 2005
)
1.45
"Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 μM) and mechanism-based (K(i) = 2.3 μM; k(inact) = 0.4 min(-1)) inhibitor of CYP3A4-catalyzed statin metabolism."( Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
Foti, RS; Pearson, JT; Rock, DA; Wahlstrom, JL; Wienkers, LC, 2011
)
1.34
"Mibefradil has been repurposed from an abandoned antihypertensive to a targeted solid tumor treatment, and it has been rescued from drug-drug interactions by using short-term dose exposure."( Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study.
Gray, L; Krouse, AJ; Macdonald, T; McCray, J, 2015
)
1.43
"Mibefradil has a higher affinity for T-type over L-type Ca2+ channels, and the drug has been used in the gastrointestinal tract to identify T-type currents."( Effect of mibefradil on sodium and calcium currents.
Bernard, CE; Farrugia, G; Gibbons, SJ; Ou, Y; Strege, PR, 2005
)
1.45
"Mibefradil has therefore an attractive profile in terms of both efficacy and safety and represents a promising first-line option to treat hypertensive patients."( Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension.
Waeber, B, 1998
)
1.29
"Mibefradil has antiischemic properties resulting from dilation of coronary and peripheral vascular smooth muscle, and a slight reduction in heart rate."( Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst, ME; Kelly, MW,
)
2.3

Actions

Mibefradil is known to inhibit various cytochrome P450 enzymes involved in drug metabolism. It plays a role in attenuating reperfusion injury of the small intestine by depressing free radical production and mucosal injury score.

ExcerptReferenceRelevance
"Mibefradil is known to inhibit various cytochrome P450 enzymes involved in drug metabolism, particularly CYP3A."( Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
Guengerich, FP; Kim, RB; Wandel, C; Wood, AJ, 2000
)
2.47
"Mibefradil plays a role in attenuating reperfusion injury of the small intestine by depressing free radical production and mucosal injury score and regulating postischemic intestinal perfusion while restoring intestinal microcirculatory blood flow and encountered histologic injury."( Mibefradil, a T-type Ca2+ channel blocker, protects against mesenteric ischemia-reperfusion-induced oxidative injury and histologic alterations in intestinal mucosa in rats.
Duran, H; Ozturk, H; Uzunlar, AK, 2006
)
2.5
"Mibefradil tended to increase afferent arteriolar diameter, whereas it did not alter media-lumen ratio."( Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure.
Fenger-Grøn, J; Mulvany, MJ; Skov, K, 1996
)
1.02

Treatment

The antihypertensive efficacy of mibefradil, a new selective transient (T)-channel calcium antagonist, was studied in eight randomized, double-blind, parallel-design trials: four placebo-controlled and four active drug-controlled versus  amlodipine or diltiazem SR.

ExcerptReferenceRelevance
"Mibefradil treatment can moderate high-fat diet-induced weight gain and improve muscle mass and function in obese mice possibly by activating AKT/mTOR signal pathway to improve lipid metabolism and inhibit obesityinduced autophagy."( [Mibefradil improves skeletal muscle mass, function and structure in obese mice].
Fu, R; Sun, Y; Wu, J; Wu, Y; Xiao, Q; Yang, Y; Yu, J, 2022
)
3.07
"Mibefradil treatment significantly decreased the MDA levels."( The effects of mibefradil, a T-type Ca2+ channels blocker, on the renal dysfunction and injury caused by ischemia-reperfusion of the rat kidney.
Gezici, A; Ozturk, H, 2005
)
1.4
"Mibefradil treatment induced regression of luminal diameter to a significant degree only in the mesenteric and femoral small arteries but decreased media thickness and media to lumen diameter in all four vascular beds."( Effect of calcium channel blockade or angiotensin-converting enzyme inhibition on structure of coronary, renal, and other small arteries in spontaneously hypertensive rats.
Li, JS; Schiffrin, EL, 1996
)
1.02
"Mibefradil treatment resulted in normalization of endothelium-dependent relaxation in mesenteric small arteries, with disappearance of acetylcholine-induced contractions, although hypertrophy and remodeling of these small arteries were not significantly affected by treatment."( Effect of short-term treatment of SHR with the novel calcium channel antagonist mibefradil on function of small arteries.
Li, JS; Schiffrin, EL, 1997
)
1.25
"Mibefradil-treated patients showed greater decreases in heart rate and the rate-pressure product at each stage of the ETT than patients treated with amlodipine or diltiazem SR."( Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
Davies, GJ; Kobrin, I; Tzivoni, D, 1997
)
2.46
"MIBEFRADIL IN THE TREATMENT OF HYPERTENSION: The antihypertensive efficacy of mibefradil, a new selective transient (T)-channel calcium antagonist, was studied in eight randomized, double-blind, parallel-design trials: four placebo-controlled and four active drug-controlled versus other calcium antagonists. "( Differential properties of mibefradil in hypertension and angina.
Kobrin, I, 1997
)
2.04
"Mibefradil treatment increased basal MAP in groups 3-5 compared to the placebo-treated MI group."( Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats.
Chung, O; Daemen, MJ; Illner, S; Jänichen, G; Rossius, B; Sandmann, S; Spitznagel, H; Unger, T; Xia, QG, 1998
)
1.29
"Mibefradil treatment significantly improved all of these parameters, whereas both amlodipine and verapamil exerted only minor effects."( Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction.
Meissner, A; Min, JY; Sandmann, S; Simon, R; Unger, T, 1999
)
1.33
"Mibefradil treatment increased MAP and dP/dtmax and decreased LVEDP and HR in infarcted rats."( Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats.
Meissner, A; Min, JY; Sandmann, S; Unger, T, 1999
)
1.29
"In mibefradil-treated animals whose treatment started 7 days before or 24 h after MI, MAP and dP/dt(max) were higher, and LVEDP was lower than in placebo-treated controls."( The T-type calcium channel blocker mibefradil reduced interstitial and perivascular fibrosis and improved hemodynamic parameters in myocardial infarction-induced cardiac failure in rats.
Bohle, RM; Dreyer, T; Sandmann, S; Unger, T, 2000
)
1.1
"Mibefradil treatment also caused a significant reduction of the polymorphonuclear leucocyte number in the paw tissue."( Protective effect of T-type calcium channel blocker in histamine-induced paw inflammation in rat.
Akpinar, E; Altaş, S; Bilici, D; Bilici, S; Dengiz, GO; Gürsan, N, 2001
)
1.03
"Mibefradil treatment, on the other hand, resulted in a significant decrease (-8%, p < 0.001) in IRT, while atenolol treatment did not change IRT."( Different effects of calcium antagonist and beta-blocker therapy on left-ventricular diastolic function in ischemic heart disease. A direct comparison of the impact of mibefradil and atenolol.
Fischer Hansen, J; Grande, P; Gustafsson, I; Hassager, C; Mickley, H; Skagen, K; Steensgaard-Hansen, F; Thygesen, K, 2001
)
1.23
"Both mibefradil and atenolol treatment significantly improves echocardiographic indices of left-ventricular diastolic function in patients with chronic stable angina. "( Different effects of calcium antagonist and beta-blocker therapy on left-ventricular diastolic function in ischemic heart disease. A direct comparison of the impact of mibefradil and atenolol.
Fischer Hansen, J; Grande, P; Gustafsson, I; Hassager, C; Mickley, H; Skagen, K; Steensgaard-Hansen, F; Thygesen, K, 2001
)
1.02
"Co-treatment with mibefradil (9 mg/kg i.p.) resulted in reversal of heat, cold and mechanical hypersensitivity in MIS-treated but not in AS-treated diabetic rats, suggesting that mibefradil and CaV3.2 AS share the same cellular target."( CaV3.2 T-type calcium channels in peripheral sensory neurons are important for mibefradil-induced reversal of hyperalgesia and allodynia in rats with painful diabetic neuropathy.
Hong, SJ; Hwang, SM; Jevtovic-Todorovic, V; Obradovic, ALj; Scarpa, J; Todorovic, SM, 2014
)
0.95
"Treatment with mibefradil (10 mg.kg(-1).d(-1)), ramipril (10 mg.kg(-1).d(-1)), or placebo was initiated 4 weeks before surgery and continued up to 6 weeks after induction of MI."( Comparison of cardioprotective effects of mibefradil and ramipril in stroke-prone spontaneously hypertensive rats.
Bitterling, H; Cleutjens, J; Daemen, MJ; Dorenkamp, M; Penz, S; Reinecke, A; Simon, R; Storz, C; Unger, T; Xia, QG, 2004
)
0.93
"Treatment with mibefradil preserved the normal morphology of the kidney and shows normal glomeruli and slight edema of the tubular cells."( The effects of mibefradil, a T-type Ca2+ channels blocker, on the renal dysfunction and injury caused by ischemia-reperfusion of the rat kidney.
Gezici, A; Ozturk, H, 2005
)
1.02
"Treatment with mibefradil or atenolol resulted in decreases from baseline in LV mass index of 11.1% (p < 0.001) and 9.1% (p < 0.001), respectively. "( A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
Cifkova, R; Höglund, C; Lindberg, E; Mimran, A; Tenczer, J; Watt, A; Wilkins, MR, 1998
)
0.94
"Treatment with mibefradil was started either 7 days before, 24 h after, or 7 days after ligation and continued for 6 weeks after MI."( The T-type calcium channel blocker mibefradil reduced interstitial and perivascular fibrosis and improved hemodynamic parameters in myocardial infarction-induced cardiac failure in rats.
Bohle, RM; Dreyer, T; Sandmann, S; Unger, T, 2000
)
0.92

Toxicity

With the 50-mg dose of mibefradil, the incidence of each adverse event was similar to, or lower than, that observed in the placebo-treated patients. 13.3% (7 of 30) of the mibecradil- treated patients reported one or more adverse events.

ExcerptReferenceRelevance
"3% (7 of 30) of the mibefradil-treated patients reported one or more adverse events compared with 13."( Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
Bernink, PJ; Braun, S; Kobrin, I; van der Vring, JA; van der Wall, EE; van Velhuisen, DJ,
)
0.76
" With the 50-mg dose of mibefradil, the incidence of each adverse event was similar to, or lower than, that observed in the placebo-treated patients."( Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
Charlon, V; Kobrin, I; Lindberg, E; Pordy, R, 1997
)
1.01
" The adverse effects of short-acting CAs in patients with heart failure include negative inotropic effects and neurohormonal activation."( Safety of calcium antagonists in patients with congestive heart failure.
Katz, S, 1997
)
0.3
" The changes in renal function parameters and the incidence of adverse events were similar in both groups."( A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension.
Bailey, R; Huysmans, FT; Kobrin, I; Mion Júnior, D; Robson, RA; Villa, G; Woittiez, AJ, 1998
)
0.56
" Safety and tolerability was similar to placebo for subgroups at 50 mg, but the incidence of adverse events was slightly higher in females, older, and lower weight patients at the 100 mg dose, particularly in reported leg oedema (7."( The efficacy and safety of mibefradil in subgroups of patients with chronic stable angina pectoris.
Charlon, V; Kobrin, I, 1998
)
0.6
" Monitoring of tacrolimus levels, which had been in the desired range (5-8 ng/ml) until recently, revealed an increase to toxic level of 54 ng/ml."( Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation.
Lochs, H; Mai, I; Ocran, KW; Plauth, M, 1999
)
0.56
" The commonest reported adverse events and reasons for stopping were malaise/lassitude, dizziness, edema and headache."( A post-marketing observational study to assess the safety of mibefradil in the community in England.
Riley, J; Shakir, SA; Wilton, LV, 2002
)
0.56
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

Mibefradil's pharmacokinetic profile indicates it can be used as a once-daily oral treatment for hypertension and chronic stable angina pectoris. With co-administration of 50 mg or 100 mg mibef radil (the recommended doses), mean digoxin Cmax values increased 1.

ExcerptReferenceRelevance
" Systemic plasma clearance, volume of distribution at steady-state and half-life after intravenous administration were as follows: ClS = 18."( Nonlinear pharmacokinetics of mibefradil in the dog.
Skerjanec, A; Tam, YK; Tawfik, S, 1996
)
0.58
" The mean +/- SD elimination half-life (t1/2) of mibefradil under steady-state conditions was 26."( Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
Crome, R; Elliott, HL; Glen, SK; MacMahon, M; Meredith, PA; Petrie, JR; Reid, JL, 1995
)
0.79
" Mibefradil's pharmacokinetic profile indicates it can be used as a once-daily oral treatment for hypertension and chronic stable angina pectoris."( Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist.
Abernethy, DR, 1997
)
1.47
"Inferentially, there is a volume of evidence that the pharmacokinetic characteristics of an antihypertensive drug translate, in part, to the haemodynamic characteristics."( Clinical relevance of optimal pharmacokinetics in the treatment of hypertension.
Meredith, PA, 1997
)
0.3
" Neither pharmacokinetic nor pharmacodynamic parameters varied as a function of renal status."( Pharmacokinetics and pharmacodynamics of mibefradil in hypertensive patients with varying degrees of renal insufficiency.
de Chatel, R; Houwing, N; Weidekamm, E; Welker, HA, 1998
)
0.57
" In this study steady-state plasma mibefradil concentrations and pharmacodynamic measurements were obtained from American and European clinical studies and analyzed using NONMEM."( Mibefradil pharmacokinetic and pharmacodynamic population analysis.
Banken, L; Welker, HA, 1998
)
2.02
" At the representative 40 mg intravenous dose mean pharmacokinetic parameters were clearance 241 +/- 76 mL min(-1), terminal exponential half-life 15."( Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
Welker, HA, 1998
)
0.6
" Oral multiple dose administration of mibefradil 50 or 100 mg once daily is associated with inhibition of the CYP3A4 pathway of metabolism, increasing the half-life and bioavailability of the parent compound."( Clinical pharmacokinetics of mibefradil.
Bullingham, R; Welker, HA; Wiltshire, H, 1998
)
0.86
" time curve (AUC0-infinity) and Cmax in the absence of mibefradil on day 1 (170 [117 to 395] ng h/mL and 91 [72 to 200] ng/mL respectively, geometric mean [95% confidence intervals]) were not significantly altered in the presence of mibefradil on day 8 (224 [174 to 381] ng h/mL and 124 [72 to 200] ng/mL) and on day 16 (200 [137 to 555] ng h/mL and 91 [74 to 184] ng/mL)."( Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics.
Becquemont, L; Funck-Brentano, C; Jaillon, P, 1999
)
1.99
"Several statistical regression models and artificial neural networks were used to predict the hepatic drug clearance in humans from in vitro (hepatocyte) and in vivo pharmacokinetic data and to identify the most predictive models for this purpose."( Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
Coassolo, P; Lavé, T; Schneider, G, 1999
)
0.3
"We explore the ramifications of the fractal geometry of the key organ for drug elimination, the liver, on pharmacokinetic data analysis."( Fractal pharmacokinetics of the drug mibefradil in the liver.
Fuite, J; Marsh, R; Tuszyński, J, 2002
)
0.59
" Studies compared the multiple-dose pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with 4 inhibitors of cytochrome P450-3A4 isoenzymes in healthy subjects."( Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson, TA, 2004
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

Mibefradil 50 or 100 mg once daily is associated with inhibition of the CYP3A4 pathway of metabolism, increasing the half-life and bioavailability of the parent compound. Mibef radil bioavailability was not affected by increasing mibef Radil doses.

ExcerptReferenceRelevance
" This effect is accompanied by increasing absolute bioavailability as the dose is increased."( Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
Welker, HA, 1998
)
0.6
" Oral multiple dose administration of mibefradil 50 or 100 mg once daily is associated with inhibition of the CYP3A4 pathway of metabolism, increasing the half-life and bioavailability of the parent compound."( Clinical pharmacokinetics of mibefradil.
Bullingham, R; Welker, HA; Wiltshire, H, 1998
)
0.86
" Mibefradil bioavailability was not affected by increasing mibefradil doses."( Nonlinear kinetics and pharmacologic response to mibefradil.
Besner, JG; Caillé, G; Clozel, JP; du Souich, P; Lefebvre, M; Welker, HA, 2000
)
1.47
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"P-glycoprotein (P-gp) is an efflux transporter involved in limiting the oral bioavailability and tissue penetration of a variety of structurally divergent molecules."( Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
Dantzig, AH; Ekins, S; Kim, RB; Lan, LB; Leake, BF; Schuetz, EG; Schuetz, JD; Shepard, RL; Wikel, JH; Winter, MA; Wrighton, SA; Yasuda, K, 2002
)
0.31
" Compound 30 showed good oral bioavailability and brain penetration across species."( Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
Adarayan, ED; Ballard, JE; Barrow, JC; Bock, MG; Bunting, PB; Connolly, TM; DiLella, AG; Doran, SM; Fox, SV; Graufelds, VK; Hartman, GD; Koblan, KS; Kraus, RL; Kuo, Y; Lindsley, CW; Magee, MM; Marino, MJ; Nuss, CE; Prueksaritanont, T; Renger, JJ; Reynolds, IJ; Rittle, KE; Schlegel, KA; Shipe, WD; Shu, Y; Tang, C; Uebele, VN; Vargas, HM; Woltmann, RF; Yang, FV; Yang, ZQ; Zrada, MM, 2008
)
0.35

Dosage Studied

Mibefradil is a well-tolerated and efficacious antihypertensive agent well suited to single daily dosing because of its intrinsic long plasma half-life. ZD7288 produces a greater effect on decreasing heart rate.

ExcerptRelevanceReference
" Dose-response curves were obtained with intravenous injection of the four drugs."( Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine.
Clozel, JP; Hess, P; Véniant, M; Wolfgang, R, 1991
)
0.28
" Highly significant dose-response relations were present across all treatment groups for exercise duration, time to angina, and time to ST-segment depression."( Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
Bakx, AL; Braun, S; Bruschke, AV; Emanuelsson, H; Kobrin, I; van der Wall, EE, 1995
)
0.56
"8, high response rate, and a significant dose-response relationship (P<."( Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
Bernink, PJ; Kobrin, I; Prager, G; Schelling, A, 1996
)
0.54
" dosing are the result of an increase in bioavailability and a reduction in systemic clearance."( Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs.
Skerjanec, A; Tam, YK; Tawfik, S, 1996
)
0.56
"Mibefradil is a well-tolerated and efficacious antihypertensive agent well suited to single daily dosing because of its intrinsic long plasma half-life."( Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
Crome, R; Elliott, HL; Glen, SK; MacMahon, M; Meredith, PA; Petrie, JR; Reid, JL, 1995
)
1.98
" Patients were evaluated at baseline and day 8 of the dosing period."( Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
Bernink, PJ; Braun, S; Kobrin, I; van der Vring, JA; van der Wall, EE; van Velhuisen, DJ,
)
0.43
" An incremental dose-response effect was observed both in clinic and ambulatory blood pressure parameters during treatment with mibefradil and nifedipine GITS alone and combined with lisinopril."( The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
Archambault, F; Dalle Ave, S; Lacourcière, Y; Lefebvre, J; Lindberg, E; Poirier, L; Ward, C, 1997
)
0.74
"The aim of this study was to determine the dose-response characteristics of the calcium antagonist, mibefradil, and to evaluate its antihypertensive efficacy and safety in varying doses in patients with mild-to-moderate hypertension."( Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
Abernethy, DR; Kobrin, I; Levine, BS; Oparil, S; Reif, MC; Shepherd, AM, 1997
)
0.79
"To evaluate the antihypertensive efficacy, tolerability, safety, and dose-response characteristics of the novel calcium antagonist, mibefradil, in combination with a diuretic regimen."( The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect.
Carney, S; Kallwellis, R; Kobrin, I; Mion, D; Ribeiro, A; Viskoper, RJ; Wing, L; Zimlichman, R, 1997
)
0.85
"This report summarizes the results of 4 double-blind, placebo-controlled studies designed to determine the efficacy, tolerability, and dose-response characteristics of the novel T-channel-selective calcium antagonist, mibefradil, in the treatment of mild-to-moderate essential hypertension."( Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
Bernink, P; Bursztyn, M; Carney, S; Kobrin, I; Oparil, S, 1997
)
0.78
"A multicenter, double-blind, placebo-controlled study of 310 elderly patients with mild-to-moderate essential hypertension was conducted in 20 sites throughout Europe, Brazil, and Israel to assess the antihypertensive efficacy, tolerability, safety, and dose-response characteristics of the novel calcium antagonist mibefradil in the elderly."( Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.
Bursztyn, M; Kadr, H; Kobrin, I; Martina, B; Oigman, W; Talberg, J; Tilvis, R, 1997
)
1.91
" In patients whose trough SDBP was greater than 90 mm Hg after 4 or 8 weeks of double-masked therapy, the dosage was titrated upward to mibefradil 100 mg or amlodipine 10 mg for the remainder of the 12-week active treatment period."( Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group.
Benz, JR; Carr, A; Karch, FE; Lunde, NM; Marbury, T; Pordy, R; Tarro, JN,
)
0.56
" The decrease in arterial pressure was smooth and sustained over the entire 24-h dosing interval."( Differential properties of mibefradil in hypertension and angina.
Kobrin, I, 1997
)
0.59
" Furthermore, a low incidence of side effects, particularly ankle edema and optimal pharmacokinetics allowing once-daily dosing would be desirable."( Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
Lüscher, TF; Noll, G, 1998
)
0.3
" A long elimination half-life makes once-daily dosing feasible, and the drug's lack of negative inotropy and reflex tachycardia distinguishes it from other available CCAs."( Mibefradil: a new class of calcium-channel antagonists.
Billups, SJ; Carter, BL, 1998
)
1.74
" It was concluded that the majority of renal-failure patients will not require a change in mibefradil dosage relative to patients with normal renal function."( Pharmacokinetics and pharmacodynamics of mibefradil in hypertensive patients with varying degrees of renal insufficiency.
de Chatel, R; Houwing, N; Weidekamm, E; Welker, HA, 1998
)
0.79
" At baseline, as well as on the last day of mibefradil dosing, complete steady-state CsA blood concentration-time profiles were characterized over a dosing interval."( Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients.
Bock, A; Peters, J; Spoendlin, M; Thiel, G; Welker, H, 1998
)
0.81
" Eight days after stopping mibefradil, tacrolimus was restarted at the same dosage and the subsequent plasma concentrations remained in the therapeutic range."( Serious interaction between mibefradil and tacrolimus.
Gallino, A; Giostra, E; Krähenbühl, S; Menafoglio, A, 1998
)
0.89
" Single-dose non-linearity was observed in the first-pass effect, although for multiple dosing oral clearance values were dose-independent and lower than for single doses."( Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
Welker, HA, 1998
)
0.6
" Consequently, mibefradil dosage adjustment is not required for patients with renal impairment."( Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
Pordy, R; Woittiez, A, 1998
)
0.95
" Dose-response curves after extracellular isoproterenol- or Ca(2+)-stimulation were recorded."( Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats.
Meissner, A; Min, JY; Sandmann, S; Unger, T, 1999
)
0.57
" The effect of MIB on the dose-response curve of externally applied noradrenaline was also studied."( Evidence for a sympatholytic effect of mibefradil in the pithed rat preparation.
Mathy, MJ; Pfaffendorf, M; van der Lee, R; van Zwieten, PA, 2000
)
0.58
" To exclude inadequate dosing as an explanation for diltiazem's inefficacy, we studied an additional group of dogs treated with 720 mg/day of diltiazem, and again noted no protective effect."( Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs.
Bénardeau, A; Fareh, S; Nattel, S, 2001
)
0.31
" An increase of holding potentials from -80 to -100 mV significantly shifted dose-response curves toward higher mibefradil concentrations, namely from a concentration of 108 +/- 21 microm (n = 7) to 288 +/- 17 microm (n = 3) for inhibition of half of the Ca(V)1."( State-dependent inhibition of inactivation-deficient Ca(V)1.2 and Ca(V)2.3 channels by mibefradil.
Bernatchez, G; Parent, L; Sauvé, R, 2001
)
0.74
" Calculation of the percent difference between the heart rate of pretreatment (before drug application) and heart rate following drug application (post-treatment) allowed us to graph a dose-response curve for both ZD7288 and mibefradil, revealing that ZD7288 produces a greater effect on decreasing heart rate."( ZD7288 and mibefradil inhibit the myogenic heartbeat in Daphnia magna indicating its dependency on HCN and T-type calcium ion channels.
Carr, TL; Khurana, T; Meeker, G; Pirtle, TJ, 2018
)
1.06
" Initial dose-response assessments on sperm hyperactivation determined the optimum concentration of P4 (10 nM), mibefradil (a non-specific Ca2+ channel antagonist; 5µM), NNC 55-0396 dihydrochloride (NNC; a CatSper antagonist; 2µM), mifepristone (a classical and membrane P4 receptor antagonist; 400nM) and AG205 (a membrane P4 receptor antagonist; 10μM)."( Progesterone induces the release of bull spermatozoa from oviductal epithelial cells.
Cronin, S; Donnellan, E; Fair, S; Romero-Aguirregomezcorta, J, 2019
)
0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
T-type calcium channel blockerAny agent that interferes with the activity of T-type calcium channels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
tetralinsCompounds containing a tetralin skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (81)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.42800.100020.879379.4328AID588453; AID588456
15-lipoxygenase, partialHomo sapiens (human)Potency39.81070.012610.691788.5700AID887
ATAD5 protein, partialHomo sapiens (human)Potency17.35120.004110.890331.5287AID493106; AID493107
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
Microtubule-associated protein tauHomo sapiens (human)Potency4.46680.180013.557439.8107AID1468
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency25.11890.00137.762544.6684AID914; AID915
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
arylsulfatase AHomo sapiens (human)Potency4.25621.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency31.40230.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.31620.00207.533739.8107AID891
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency58.04790.01262.451825.0177AID485313
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency23.73590.316212.443531.6228AID902; AID924
D(1A) dopamine receptorHomo sapiens (human)Potency12.58930.02245.944922.3872AID488981; AID488983
chromobox protein homolog 1Homo sapiens (human)Potency44.66840.006026.168889.1251AID488953
mitogen-activated protein kinase 1Homo sapiens (human)Potency19.95260.039816.784239.8107AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency23.28090.00669.809418.4927AID1347050
flap endonuclease 1Homo sapiens (human)Potency5.97280.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency73.07800.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency15.11910.00378.618923.2809AID2660; AID2666; AID2667; AID2668
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.31620.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency26.63210.00106.000935.4813AID943; AID944
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency2.61410.316212.765731.6228AID881
Integrin beta-3Homo sapiens (human)Potency31.62280.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency31.62280.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Alpha-synucleinHomo sapiens (human)Potency29.09290.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency2.61410.00638.235039.8107AID881
D(1A) dopamine receptorSus scrofa (pig)Potency10.39920.00378.108123.2809AID2667
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency15.84890.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Voltage-dependent L-type calcium channel subunit alpha-1CCavia porcellus (domestic guinea pig)IC50 (µMol)0.15600.02201.64228.9000AID1207190
Voltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)IC50 (µMol)1.04760.03700.89152.5000AID1058669; AID1128358; AID1367943; AID1662453; AID1710941; AID241129; AID270463; AID283966; AID284280; AID287272; AID301834; AID305157; AID305293; AID365487; AID478835; AID490100; AID490101; AID499459; AID499464; AID549673; AID614614; AID733230; AID82383
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)0.33300.00032.63119.0000AID1207190; AID1207751
Voltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)IC50 (µMol)0.41220.03201.04793.6000AID1242978; AID1367944; AID319994; AID499460; AID528255; AID732968
Bile salt export pumpHomo sapiens (human)IC50 (µMol)25.00000.11007.190310.0000AID1443980
Sodium channel protein type 2 subunit alphaRattus norvegicus (Norway rat)IC50 (µMol)0.50000.00401.14854.7300AID1367952
ATP-dependent translocase ABCB1Mus musculus (house mouse)IC50 (µMol)10.00000.06404.012610.0000AID150754; AID681128
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)1.58000.00022.318510.0000AID150752; AID150755; AID679606; AID680134; AID681122
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.25750.00011.753610.0000AID54923; AID705585
Cytochrome P450 3A4Homo sapiens (human)Ki1.79500.00011.41629.9000AID1215385; AID705592
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.06300.00002.015110.0000AID732966
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)2.14000.00002.800510.0000AID1210069
Sodium channel protein type 4 subunit alphaRattus norvegicus (Norway rat)IC50 (µMol)0.50000.06900.28450.5000AID1367951
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)1.34000.00031.38338.4000AID301834
ATP-dependent translocase ABCB1Mus musculus (house mouse)IC50 (µMol)7.40000.20004.713010.0000AID150753; AID681119
Sodium channel protein type 1 subunit alphaHomo sapiens (human)IC50 (µMol)0.98000.00232.82969.0000AID1207161
Sodium channel protein type 4 subunit alphaHomo sapiens (human)IC50 (µMol)0.98000.00013.507510.0000AID1207161
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)2.14000.01202.53129.4700AID1210069
Voltage-dependent L-type calcium channel subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)1.00001.00001.00001.0000AID1367949
Voltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)IC50 (µMol)0.87800.04004.113710.0000AID478837; AID528256
Sodium channel protein type 7 subunit alphaHomo sapiens (human)IC50 (µMol)0.98000.03603.73359.0000AID1207161
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)0.33300.00032.59559.0000AID1207190; AID1207751
Voltage-dependent N-type calcium channel subunit alpha-1BRattus norvegicus (Norway rat)IC50 (µMol)1.00000.08000.32001.0000AID1367949
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)1.45430.00091.901410.0000AID1207220; AID1242987; AID1367947; AID1594450; AID161281; AID240820; AID243151; AID243188; AID390817; AID408340; AID420668; AID46662; AID478836; AID549674; AID620582; AID732970; AID733228
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki0.27150.00211.840710.0000AID290939; AID290940
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)0.33300.00032.63119.0000AID1207190; AID1207751
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)66.18630.00032.25459.6000AID1207190; AID1207664; AID1207665; AID1207751; AID1242979; AID1367946
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)0.74000.00033.64849.2000AID1207161; AID1367950
Sodium channel protein type 9 subunit alphaHomo sapiens (human)IC50 (µMol)0.74000.00602.77499.0000AID1207161; AID1367953
Calcium release-activated calcium channel protein 1Homo sapiens (human)IC50 (µMol)76.05000.50004.25009.8000AID1330309; AID1330311
Sodium channel protein type 2 subunit alphaHomo sapiens (human)IC50 (µMol)0.98000.00003.740110.0000AID1207161
Sodium channel protein type 3 subunit alphaHomo sapiens (human)IC50 (µMol)0.98000.00532.80859.0000AID1207161
Voltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)IC50 (µMol)0.41870.08600.65472.5000AID1367945; AID390816; AID499461
Sodium channel protein type 11 subunit alphaHomo sapiens (human)IC50 (µMol)0.98000.03004.36959.0000AID1207161
Sodium channel protein type 8 subunit alphaHomo sapiens (human)IC50 (µMol)0.98000.00113.47059.0000AID1207161
Sodium channel protein type 10 subunit alphaHomo sapiens (human)IC50 (µMol)0.98000.00803.17529.0000AID1207161
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium channel subfamily K member 2Homo sapiens (human)EC50 (µMol)0.50000.18702.72248.1800AID1802150
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)Ks0.69000.01900.21000.6900AID1215382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (414)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
sinoatrial node developmentVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
chemical synaptic transmissionVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
response to nickel cationVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
regulation of membrane potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
calcium ion importVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
SA node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
AV node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
SA node cell to atrial cardiac muscle cell signalingVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
AV node cell to bundle of His cell signalingVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
cardiac ventricle developmentPotassium channel subfamily K member 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayPotassium channel subfamily K member 2Homo sapiens (human)
memoryPotassium channel subfamily K member 2Homo sapiens (human)
response to mechanical stimulusPotassium channel subfamily K member 2Homo sapiens (human)
response to axon injuryPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationPotassium channel subfamily K member 2Homo sapiens (human)
cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium channel subfamily K member 2Homo sapiens (human)
cochlea developmentPotassium channel subfamily K member 2Homo sapiens (human)
positive regulation of cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of DNA biosynthetic processPotassium channel subfamily K member 2Homo sapiens (human)
stabilization of membrane potentialPotassium channel subfamily K member 2Homo sapiens (human)
muscle contractionVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
muscle organ developmentVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
myoblast fusionVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
regulation of heart contractionVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
aldosterone biosynthetic processVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
cellular response to hormone stimulusVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
cortisol biosynthetic processVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
cellular response to potassium ionVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
regulation of membrane potentialVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
calcium ion importVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
inorganic cation transmembrane transportVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
positive regulation of acrosome reactionVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
sodium ion transportSodium channel protein type 1 subunit alphaHomo sapiens (human)
adult walking behaviorSodium channel protein type 1 subunit alphaHomo sapiens (human)
determination of adult lifespanSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal action potential propagationSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
nerve developmentSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuromuscular process controlling postureSodium channel protein type 1 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painSodium channel protein type 1 subunit alphaHomo sapiens (human)
establishment of localization in cellSodium channel protein type 1 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 1 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
regulation of presynaptic membrane potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 1 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
muscle contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
regulation of skeletal muscle contraction by action potentialSodium channel protein type 4 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
modulation of chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
response to amyloid-betaVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
osmosensory signaling pathwaySodium channel protein type 7 subunit alphaHomo sapiens (human)
response to bacteriumSodium channel protein type 7 subunit alphaHomo sapiens (human)
cellular homeostasisSodium channel protein type 7 subunit alphaHomo sapiens (human)
sodium ion homeostasisSodium channel protein type 7 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 7 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 7 subunit alphaHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
inflammatory responseSodium channel protein type 9 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 9 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 9 subunit alphaHomo sapiens (human)
post-embryonic developmentSodium channel protein type 9 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perceptionSodium channel protein type 9 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 9 subunit alphaHomo sapiens (human)
store-operated calcium entryCalcium release-activated calcium channel protein 1Homo sapiens (human)
adaptive immune responseCalcium release-activated calcium channel protein 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayCalcium release-activated calcium channel protein 1Homo sapiens (human)
positive regulation of insulin secretionCalcium release-activated calcium channel protein 1Homo sapiens (human)
positive regulation of adenylate cyclase activityCalcium release-activated calcium channel protein 1Homo sapiens (human)
regulation of calcium ion transportCalcium release-activated calcium channel protein 1Homo sapiens (human)
positive regulation of calcium ion transportCalcium release-activated calcium channel protein 1Homo sapiens (human)
mammary gland epithelium developmentCalcium release-activated calcium channel protein 1Homo sapiens (human)
calcium ion importCalcium release-activated calcium channel protein 1Homo sapiens (human)
calcium ion transmembrane transportCalcium release-activated calcium channel protein 1Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayCalcium release-activated calcium channel protein 1Homo sapiens (human)
ligand-gated ion channel signaling pathwayCalcium release-activated calcium channel protein 1Homo sapiens (human)
sodium ion transportSodium channel protein type 2 subunit alphaHomo sapiens (human)
nervous system developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stressSodium channel protein type 2 subunit alphaHomo sapiens (human)
neuron apoptotic processSodium channel protein type 2 subunit alphaHomo sapiens (human)
memorySodium channel protein type 2 subunit alphaHomo sapiens (human)
determination of adult lifespanSodium channel protein type 2 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 2 subunit alphaHomo sapiens (human)
dentate gyrus developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
nerve developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
myelinationSodium channel protein type 2 subunit alphaHomo sapiens (human)
cellular response to hypoxiaSodium channel protein type 2 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 2 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 2 subunit alphaHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
sodium ion transportSodium channel protein type 3 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 3 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 3 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 3 subunit alphaHomo sapiens (human)
signal transductionVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
neuronal action potentialVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
sleepVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
thigmotaxisSodium channel protein type 11 subunit alphaHomo sapiens (human)
acute inflammatory responseSodium channel protein type 11 subunit alphaHomo sapiens (human)
chronic inflammatory responseSodium channel protein type 11 subunit alphaHomo sapiens (human)
axonogenesisSodium channel protein type 11 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to heatSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to xenobiotic stimulusSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to high light intensitySodium channel protein type 11 subunit alphaHomo sapiens (human)
protein kinase A signalingSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to auditory stimulusSodium channel protein type 11 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 11 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to prostaglandin ESodium channel protein type 11 subunit alphaHomo sapiens (human)
thermosensory behaviorSodium channel protein type 11 subunit alphaHomo sapiens (human)
mast cell degranulationSodium channel protein type 11 subunit alphaHomo sapiens (human)
cell motilitySodium channel protein type 11 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
reflexSodium channel protein type 11 subunit alphaHomo sapiens (human)
micturitionSodium channel protein type 11 subunit alphaHomo sapiens (human)
skeletal muscle organ developmentSodium channel protein type 11 subunit alphaHomo sapiens (human)
artery developmentSodium channel protein type 11 subunit alphaHomo sapiens (human)
behavioral response to acetic acid induced painSodium channel protein type 11 subunit alphaHomo sapiens (human)
behavioral response to formalin induced painSodium channel protein type 11 subunit alphaHomo sapiens (human)
cellular response to coldSodium channel protein type 11 subunit alphaHomo sapiens (human)
calcium ion transmembrane transportSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to nitric oxideSodium channel protein type 11 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 11 subunit alphaHomo sapiens (human)
action potential initiationSodium channel protein type 11 subunit alphaHomo sapiens (human)
sensory perception of itchSodium channel protein type 11 subunit alphaHomo sapiens (human)
calcitonin gene-related peptide receptor signaling pathwaySodium channel protein type 11 subunit alphaHomo sapiens (human)
small intestine smooth muscle contractionSodium channel protein type 11 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 11 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 11 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 8 subunit alphaHomo sapiens (human)
nervous system developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
peripheral nervous system developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 8 subunit alphaHomo sapiens (human)
optic nerve developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
myelinationSodium channel protein type 8 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 8 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 8 subunit alphaHomo sapiens (human)
regulation of heart rateSodium channel protein type 10 subunit alphaHomo sapiens (human)
sensory perceptionSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of monoatomic ion transmembrane transportSodium channel protein type 10 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 10 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of cardiac muscle contractionSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 10 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of presynaptic membrane potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (138)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
low voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
scaffold protein bindingVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
outward rectifier potassium channel activityPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion leak channel activityPotassium channel subfamily K member 2Homo sapiens (human)
voltage-gated monoatomic ion channel activityVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
protein bindingVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
low voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
metal ion bindingVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
scaffold protein bindingVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Mus musculus (house mouse)
voltage-gated sodium channel activitySodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 4 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 4 subunit alphaHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
amyloid-beta bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
protein bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
ATP bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
sodium channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 7 subunit alphaHomo sapiens (human)
osmolarity-sensing monoatomic cation channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 9 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 9 subunit alphaHomo sapiens (human)
calcium channel activityCalcium release-activated calcium channel protein 1Homo sapiens (human)
protein bindingCalcium release-activated calcium channel protein 1Homo sapiens (human)
calmodulin bindingCalcium release-activated calcium channel protein 1Homo sapiens (human)
store-operated calcium channel activityCalcium release-activated calcium channel protein 1Homo sapiens (human)
identical protein bindingCalcium release-activated calcium channel protein 1Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 2 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 2 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 2 subunit alphaHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 3 subunit alphaHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
protein bindingVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 11 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 8 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
ATP bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
sodium ion bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 10 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 10 subunit alphaHomo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (103)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoplasmVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
synapseVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
endoplasmic reticulum membranePotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
cell surfacePotassium channel subfamily K member 2Homo sapiens (human)
apical plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
neuronal cell bodyPotassium channel subfamily K member 2Homo sapiens (human)
calyx of HeldPotassium channel subfamily K member 2Homo sapiens (human)
astrocyte projectionPotassium channel subfamily K member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
membraneVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneATP-dependent translocase ABCB1Mus musculus (house mouse)
plasma membraneSodium channel protein type 1 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 1 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 1 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 1 subunit alphaHomo sapiens (human)
nuclear bodySodium channel protein type 1 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 1 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 1 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal cell bodySodium channel protein type 1 subunit alphaHomo sapiens (human)
axon initial segmentSodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 1 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 4 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 4 subunit alphaHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
synapseVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
neuronal cell bodyVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
plasma membraneSodium channel protein type 7 subunit alphaHomo sapiens (human)
glial cell projectionSodium channel protein type 7 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 7 subunit alphaHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 9 subunit alphaHomo sapiens (human)
axonSodium channel protein type 9 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 9 subunit alphaHomo sapiens (human)
plasma membraneCalcium release-activated calcium channel protein 1Homo sapiens (human)
membraneCalcium release-activated calcium channel protein 1Homo sapiens (human)
basolateral plasma membraneCalcium release-activated calcium channel protein 1Homo sapiens (human)
plasma membrane raftCalcium release-activated calcium channel protein 1Homo sapiens (human)
membrane raftCalcium release-activated calcium channel protein 1Homo sapiens (human)
calcium channel complexCalcium release-activated calcium channel protein 1Homo sapiens (human)
membraneCalcium release-activated calcium channel protein 1Homo sapiens (human)
plasma membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 2 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 2 subunit alphaHomo sapiens (human)
axonSodium channel protein type 2 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 2 subunit alphaHomo sapiens (human)
paranode region of axonSodium channel protein type 2 subunit alphaHomo sapiens (human)
presynaptic membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 2 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 2 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
sarcoplasmSodium channel protein type 3 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 3 subunit alphaHomo sapiens (human)
plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
plasma membraneSodium channel protein type 11 subunit alphaHomo sapiens (human)
axonSodium channel protein type 11 subunit alphaHomo sapiens (human)
neuronal cell bodySodium channel protein type 11 subunit alphaHomo sapiens (human)
axonal growth coneSodium channel protein type 11 subunit alphaHomo sapiens (human)
C-fiberSodium channel protein type 11 subunit alphaHomo sapiens (human)
extracellular exosomeSodium channel protein type 11 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 11 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 8 subunit alphaHomo sapiens (human)
cell junctionSodium channel protein type 8 subunit alphaHomo sapiens (human)
axonSodium channel protein type 8 subunit alphaHomo sapiens (human)
cytoplasmic vesicleSodium channel protein type 8 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 8 subunit alphaHomo sapiens (human)
axon initial segmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
presynaptic active zone membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
parallel fiber to Purkinje cell synapseSodium channel protein type 8 subunit alphaHomo sapiens (human)
postsynaptic density membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 8 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 8 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 10 subunit alphaHomo sapiens (human)
axonSodium channel protein type 10 subunit alphaHomo sapiens (human)
presynaptic membraneSodium channel protein type 10 subunit alphaHomo sapiens (human)
extracellular exosomeSodium channel protein type 10 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 10 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 10 subunit alphaHomo sapiens (human)
clathrin complexSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (279)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID683699Antimalarial activity against liver stages of Plasmodium yoelii yoelii2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Targeting the liver stage of malaria parasites: a yet unmet goal.
AID1058669Inhibition of t-type Cav3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of 50 ms depolarizing voltage step-induced current by whole cell patch-clamp method2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers.
AID1330316Antagonist activity at rat TRPM8 expressed in HEK293 cells assessed as inhibition of menthol-stimulated Ca2+ flux up to 100 uM after 30 mins by calcium-4 dye based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID290941Ratio of Ki for hERG by SPA to Ki for hERG by fluorescence polarization assay in HEK293 cells2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
AID1711066Induction of cell cycle arrest in human A549 cells assessed as accumulation at S phase at 10 uM after 24 hrs by flow cytometric analysis (Rvb = 17.6%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID301834Inhibition of T-type calcium channel Cav3.1 alpha-1G subunit expressed in HEK293 cells assessed as calcium current by patch-clamp assay2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Discovery of potent T-type calcium channel blocker.
AID1662452Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline derivatives as novel T-type calcium channel blockers.
AID150752Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID499458Inhibition of N-type Alpha-1B channel expressed in HEK293 cells by whole-cell patch-clamp method2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity.
AID499461Inhibition of T-type Cav3.3 channel2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity.
AID1215382Binding affinity to CYP3A4 (unknown origin)2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID390872Cardiotoxicity in iv dosed CV dog model assessed as change in PR intervals up to 6.4 uM plasma concentration2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID478837Inhibition of N-type calcium channel Alpha-1B2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers.
AID1128389Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by flow cytometry (Rvb = 21.6 %)2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID1333092Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on mechanical allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 3 hrs relative to gabapentin2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID1333062Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on cold allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 1 hr relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID1333093Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on mechanical allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 5 hrs relative to gabapentin2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID1662449Inhibition of human Cav3.2 expressed in tsA-201 cells at 10uM by patch clamp electrophysiology2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline derivatives as novel T-type calcium channel blockers.
AID1333095Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on cold allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 5 hrs relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID528257Selectivity for T-type calcium channel subunit alpha-1H over L-type calcium channel subunit alpha-1C2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists.
AID1710941Inhibition of T type calcium channel Cav3.1 (unknown origin) expressed in HEK293T cells by patch clamp method relative to control2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID287272Inhibition of T type calcium channel subunit alpha-1G expressed in HEK293 cells assessed as effect on T-type calcium currents by patch clamp method2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Lead discovery and optimization of T-type calcium channel blockers.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1207161Inhibition of Na channel (species unknown)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1210074Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1367944Inhibition of Cav3.2 (unknown origin)2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
AID305156Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit at 10 uM by whole-cell patch clamp method2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Synthesis and biological evaluation of novel T-type calcium channel blockers.
AID305155Inhibition of T-type calcium channel Cav3.2 expressed in HEK293 cells coexpressing alpha-1H subunit at 100 uM by two-electrode voltage clamp method2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Synthesis and biological evaluation of novel T-type calcium channel blockers.
AID1711067Induction of cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by flow cytometric analysis (Rvb = 21.6%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells.
AID390874Cardiotoxicity in iv dosed CV dog model assessed as blood pressure up to 6.4 uM plasma concentration2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
AID305159Selectivity index, ratio of T-type calcium channel Cav3.2 to N-type calcium channel at 10 uM2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Synthesis and biological evaluation of novel T-type calcium channel blockers.
AID150757P-gp activity was measured by a direct transport assay, using polarized LLC-MDR1 epithelial cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID270464Ability to block calcium channel N type 2.2v expressed in HEK293 cells at 10 uM by whole cell patch clamp method2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers.
AID342909Antagonist activity at T type calcium channel alpha1G expressed in HEK293 cells assessed as inhibition of peak currents at 10 uM by whole-cell patch-clamp method2008Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15
Synthesis and evaluation of alpha,alpha'-disubstituted phenylacetate derivatives for T-type calcium channel blockers.
AID21854In vivo clearance in dog.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1128390Cell cycle arrest in human A549 cells assessed as accumulation at sub-G1 phase at 10 uM after 48 hrs by flow cytometry (Rvb = 4.9 %)2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID305157Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit by whole-cell patch clamp method2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Synthesis and biological evaluation of novel T-type calcium channel blockers.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID44914In vitro inhibitory effect on alpha-1H T-type [Ca2+] channels expressed in Xenopus oocytes at 100 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers.
AID1210070Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID620581Inhibition of T-type calcium channel alpha1G expressed in human HEK293 cells assessed as KCl-induced depolarization at 10 uM after 60 mins by FDSS6000 assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID549669Inhibition of T-type alpha1G calcium channel expressed in HEK293 cells assessed as Kcl-induced depolarization at 10 uM2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Facile synthesis and biological evaluation of 3,3-diphenylpropanoyl piperazines as T-type calcium channel blockers.
AID390873Cardiotoxicity in iv dosed CV dog model assessed as heart rate up to 6.4 uM plasma concentration2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
AID365487Antagonist activity at T type calcium channel alpha1G expressed in HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method2008Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15
Synthesis and evaluation of alpha,alpha'-disubstituted phenylacetate derivatives for T-type calcium channel blockers.
AID1662448Inhibition of human Cav3.1 expressed in tsA-201 cells at 10uM by patch clamp electrophysiology2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline derivatives as novel T-type calcium channel blockers.
AID1333090Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on mechanical allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 3 hrs relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID21851In vitro clearance in human in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID290940Binding affinity at hERG expressed in HEK293 cells by fluorescence polarization assay2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1243001Antihypertensive activity in freely moving conscious spontaneously hypertensive rat at assessed as reduction in mean arterial pressure at 10 mg/kg, po administered as single dose in morning at end of wake phase measured after 6 hrs by telemetry2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.
AID499459Inhibition of T-type Cav3.1 channel2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity.
AID1210072Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID301830Inhibition of T-type calcium channel Cav3.1 alpha-1G subunit expressed in HEK293 cells assessed as calcium current at 10 uM by patch-clamp assay2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Discovery of potent T-type calcium channel blocker.
AID499464Inhibition of T-type alpha1G channel expressed in HEK293 cells by whole-cell patch-clamp method2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity.
AID1367947Inhibition of human ERG2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
AID150759P-gp activity was measured by a direct transport assay, using polarized LLC-mdr1a epithelial cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID681120TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID705592Time dependent inhibition of CYP3A42012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID270465Selectivity for calcium channel N type 2.2v over calcium channel T type 3.1v2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers.
AID301831Inhibition of T-type calcium channel Cav3.1 alpha-1G subunit expressed in HEK293 cells assessed as calcium current at 10 uM by high throughput screening2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Discovery of potent T-type calcium channel blocker.
AID1128388Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 10 uM after 24 hrs by flow cytometry (Rvb = 17.6 %)2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID1594449Stability in human liver microsomes assessed as parent compound remaining measured after 30 mins2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model.
AID733227Selectivity ratio of IC50 for human ERG to IC50 for alpha-1G calcium channel in human HEK293 cells2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1367943Inhibition of Cav3.1 (unknown origin)2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
AID1215389Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent methyl hydroxylamine2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID243723Percent inhibition of T-type [Ca2+] channel (alpha1H) stably expressed in Xenopus oocytes at 100 uM2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers.
AID1243002Antihypertensive activity in freely moving conscious spontaneously hypertensive rat at assessed as area between curve for reduction in mean arterial pressure at 10 mg/kg, po administered as single dose in morning at end of wake phase by telemetry2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.
AID390816Inhibition of T-type calcium channel alpha1I by FLIPR2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
AID150756Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1215387Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent semicarbazide2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID499460Inhibition of T-type Cav3.2 channel2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity.
AID1333094Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on cold allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 3 hrs relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID319996Antagonist activity at L-type calcium channel in rat aorta2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core.
AID1128355Cytotoxicity against human A549 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID1662454Inhibition of human Cav3.2 expressed in tsA-201 cells by patch clamp electrophysiology2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline derivatives as novel T-type calcium channel blockers.
AID1330311Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+ by PBX-ba2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID549674Inhibition of human hERG2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Facile synthesis and biological evaluation of 3,3-diphenylpropanoyl piperazines as T-type calcium channel blockers.
AID1128383Selectivity ratio of IC50 for human A549 cells to IC50 for human MIAPaCa2 cells2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID283966Inhibition of T-type calcium channel Cav3.1 with alpha-1G subunit by patch clamp assay2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives.
AID1181449Stability in human liver microsomes assessed as compound remaining at 1 uM after 30 mins by LC/MS analysis2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID1333048Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on mechanical allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 1 hr relative to gabapentin2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID241129Inhibition of T-type [Ca2+] channel (alpha1G) expressed in HEK293 cells2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers.
AID1207665Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1210071Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID150753Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1367951Inhibition of rat skeletal muscle Nav1.4 expressed in HEK293 cells by whole cell voltage clamp method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
AID1128386Cell cycle arrest in human A549 cells assessed as accumulation at sub-G1 phase at 10 uM after 24 hrs by flow cytometry (Rvb = 7.8 %)2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID1207751Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID390883Selectivity for T-type calcium channel over L-type calcium channel2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
AID1128357Inhibition of T-type CaV3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of calcium current at 1 uM by whole cell patch-clamp method2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID614615Bradycardic activity in Hartley guinea pig right atrial muscles assessed as reduction of initial spontaneous beat rate after 30 mins2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and pharmacological evaluation of 1-alkyl-N-[2-ethyl-2-(4-fluorophenyl)butyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents.
AID150758P-gp activity was measured by a direct transport assay, using polarized LLC-PK1 epithelial cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID478836Inhibition of human ERG2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers.
AID46662K+ channel blocking activity in COS-7 African green monkey kidney derived cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID390817Inhibition of human ERG2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
AID1058667Cytotoxicity against human A2780 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers.
AID301832Inhibition of N-type calcium channel Cav3.1 alpha-1B subunit expressed in HEK293 cells assessed as calcium current at 10 uM by patch-clamp assay2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Discovery of potent T-type calcium channel blocker.
AID490101Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by automated patch-clamp assay2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Synthesis and biological evaluation of oxazole derivatives as T-type calcium channel blockers.
AID1207220Inhibition of hERG K channel2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1367949Inhibition of rat Cav2.2-alpha1beta/beta3 expressed in HEK293 cells assessed as decrease in calcium mobilization response to KCl after 1 hr by Fluo-4-AM dye-based FLIPR assay2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
AID1630248Inhibition of T-type alpha1G channel (unknown origin) expressed in HEK293 cells at 10 uM by fluorescence-based HTS assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and evaluation of 6-pyrazoylamido-3N-substituted azabicyclo[3,1,0]hexane derivatives as T-type calcium channel inhibitors for treatment of neuropathic pain.
AID21852In vitro clearance in rat in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID528255Antagonist activity against T-type calcium channel subunit alpha-1H assessed as inactivation of channel current by cell based patch clamp assay2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists.
AID490100Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by manual patch-clamp assay2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Synthesis and biological evaluation of oxazole derivatives as T-type calcium channel blockers.
AID733230Inhibition of alpha-1G calcium channel in human HEK293 cells by whole-cell patch-clamp method2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID270461Ability to block calcium channel T type 3.2v expressed in Xenopus oocytes at 100 uM by two-microelectrode voltage-clamp method2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers.
AID270463Ability to block calcium channel T type 3.1v expressed in HEK293 cells by whole cell patch clamp method2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers.
AID589152Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation and midazolam 1'-hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1210073Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1711086Induction of cell cycle arrest in human A549 cells assessed as accumulation at S phase at 10 uM after 48 hrs by flow cytometric analysis (Rvb = 12%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells.
AID1215383Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes at 10 uM measured after 1.5 min in presence of 1 mM NADPH2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID549673Inhibition of T-type alpha1G calcium channel expressed in HEK293 cells assessed as Kcl-induced depolarization2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Facile synthesis and biological evaluation of 3,3-diphenylpropanoyl piperazines as T-type calcium channel blockers.
AID1594447Inhibition of recombinant human Cav3.1 expressed in HEK293 cells assessed as reduction in KCl-induced increase in intracellular calcium level at 10 uM by fura-2 AM indicator based FDSS assay relative to control2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model.
AID1711085Induction of cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 10 uM after 48 hrs by flow cytometric analysis (Rvb = 57.8%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells.
AID620582Inhibition of human ERG by patch clamp assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers.
AID1367950Inhibition of human heart Nav1.5 expressed in HEK293 cells by whole cell voltage clamp method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
AID1215396Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes assessed as decrease in CYP3A4-CO binding at 10 uM preincubated for 5 mins measured after overnight washout with 100 mM potassium phosphate buffer by LC-tandem mass spectrometry an2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID733228Inhibition of human ERG2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers.
AID54923Inhibition of human cytochrome P450 3A42003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1215399Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes assessed as decrease in heme level at 10 uM preincubation for 5 mins by LC/UV/MS analysis in presence of 1 mM NADPH2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1242980Increase in coronary flow in Wistar rat Langendorff isolated perfused heart2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.
AID681119TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1128387Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs by flow cytometry (Rvb = 53.1 %)2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID287271Inhibition of T type calcium channel subunit alpha-1G expressed in HEK293 cells assessed as effect on T-type calcium currents at 10 uM by patch clamp method2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Lead discovery and optimization of T-type calcium channel blockers.
AID705585Reversible inhibition of CYP3A42012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1367953Inhibition of human Nav1.7 expressed in HEK293 cells by whole cell voltage clamp method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
AID1367952Inhibition of rat brain Nav1.2 expressed in HEK293 cells by whole cell voltage clamp method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
AID1058670Inhibition of t-type Cav3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of 50 ms depolarizing voltage step-induced current at 1 uM by whole cell patch-clamp method relative to control2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers.
AID29813Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID732966Inhibition of human recombinant CYP2D6-mediated 7-methoxy-4(aminomethyl)-coumarine degradation2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor.
AID1480298Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID1333063Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on cold allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 1 hr relative to gabapentin2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID270462Ability to block calcium channel T type 3.1v expressed in HEK293 cells at 10 uM by whole cell patch clamp method2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers.
AID519607Cytotoxicity against Hepatocyte cells assessed as cell viability by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1330317Antagonist activity at Cav2.2 in human SH-SY5Y cells assessed as inhibition of KCl/CaCl2-stimulated Ca2+ flux up to 100 uM after 30 mins in presence of nifedipine by Fuo-4 dye based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID1215385Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1058666Cytotoxicity against human paclitaxel-resistant A2780T cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers.
AID1333091Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on mechanical allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 5 hrs relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID1128391Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs by flow cytometry (Rvb = 57.8 %)2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID1662455Inhibition of human Cav3.3 expressed in tsA-201 cells by patch clamp electrophysiology2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline derivatives as novel T-type calcium channel blockers.
AID1242987Inhibition of human ERG expressed in HEK cells by patch clamp assay2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.
AID1330309Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1207664Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1164252Stability in human liver microsomes assessed as parent compound remaining at 1 uM after 30 mins by LC/MS method2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1662450Inhibition of human Cav3.3 expressed in tsA-201 cells at 10uM by patch clamp electrophysiology2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline derivatives as novel T-type calcium channel blockers.
AID1710940Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells.
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID150751Inhibition of P-glycoprotein using ATPase in MDR1 membranes2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1242978Inhibition of recombinant Cav3.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.
AID499472Inhibition of L-type calcium channel2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity.
AID1215386Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent glutathione2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID1215401Ratio of Kinact to Ki for recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID287269Inhibition of T type calcium channel subunit alpha-1H expressed in Xenopus oocytes at 100 uM by FDSS assay2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Lead discovery and optimization of T-type calcium channel blockers.
AID1207190Inhibition of voltage-gated L-type Ca channel (species unknown)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID528256Antagonist activity against L-type calcium channel subunit alpha-1C assessed as inactivation of channel current by cell based patch clamp assay2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists.
AID19468Partition coefficient (logP)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID519608Selectivity index, ratio of TC50 for hepatocytes to IC50 for Plasmodium yoelii 2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID240820Inhibitory concentration against IKr potassium channel2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
AID1333097Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on cold allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 5 hrs relative to gabapentin2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID21849In vitro clearance in dog in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID21859In vivo clearance in rat.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID1215393Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent catalase2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID150754Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID284280Inhibition of alpha-1G T-type calcium channel expressed in HEK293 cells by electrophysiological method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
3D pharmacophore based virtual screening of T-type calcium channel blockers.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID679606TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells2000Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 28, Issue:8
Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
AID1128356Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID305293Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit and Kir2.1 potassium channel by patch-clamp assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Design, synthesis, and biological evaluation of 1,3-dioxoisoindoline-5-carboxamide derivatives as T-type calcium channel blockers.
AID733229Inhibition of alpha-1G calcium channel in human HEK293 cells at 10 uM by whole-cell patch-clamp method2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers.
AID614614Inhibition of human Cav3.1 alpha1G expressed in HEK293 cells assessed as inhibition of calcium influx by FLIPR assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and pharmacological evaluation of 1-alkyl-N-[2-ethyl-2-(4-fluorophenyl)butyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents.
AID1215397Binding affinity to recombinant CYP3A4 (unknown origin) expressed in baculosomes assessed as metabolite intermediate complex formation at 10 uM for 0 to 45 mins by UV-spectrometry2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID1242979Inhibition of recombinant Cav1.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.
AID1594450Inhibition of human ERG by whole-cell patch clamp method2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model.
AID305158Inhibition of N-type calcium channel expressed in HEK293 cells co-expressing Alpha-1B subunit at 10 uM2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Synthesis and biological evaluation of novel T-type calcium channel blockers.
AID150755Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID21857In vivo clearance in human.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID390818Displacement of [3H]diltiazem from L-type calcium channel in rabbit muscle cells2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
AID243722Percent inhibition of T-type [Ca2+] channel (alpha1G) expressed in HEK293 cells at 10 uM2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers.
AID1242984Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.
AID243188Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
A two-state homology model of the hERG K+ channel: application to ligand binding.
AID680134TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells2002Molecular pharmacology, May, Volume: 61, Issue:5
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
AID680290TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Mibefradil: 18 uM) in MDR1-expressing NIH-3T3 cells2004Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID44912In vitro inhibition of alpha-1G T-type [Ca2+] channels expressed in HEK293 cells at 10 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers.
AID1215391Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent N-acetyl lysine2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID732970Inhibition of human ERG expressed in CHO cells by IONWORKS assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor.
AID1128393Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 10 uM after 48 hrs by flow cytometry (Rvb = 25.4 %)2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID490099Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current at 10 uM by fluorescence based HTS FDSS6000 assay2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Synthesis and biological evaluation of oxazole derivatives as T-type calcium channel blockers.
AID732968Inhibition of human T-type calcium channel Cav3.2 expressed in T-Rex293 cells by whole cell patch clamp assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor.
AID243721Percent inhibition of N-type [Ca2+] channel (Alpha-1B) expressed in HEK293 cells at 10 uM2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers.
AID1333061Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on mechanical allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 1 hr relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID1711087Induction of cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 10 uM after 48 hrs by flow cytometric analysis (Rvb = 25.4%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells.
AID1333096Antineuropathic pain activity in rat spinal nerve ligation model assessed as effect on cold allodynia by measuring frequency of paw withdrawal at 100 mg/kg, po measured at 3 hrs relative to gabapentin2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
AID1398113Inhibition of T-type calcium channel in human Jurkat cells assessed as suppression of thapsigargin-induced intracellular calcium flux after 1 hr by indo-1 dye-based spectrofluorometric method2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Design and synthesis of novel anti-hyperalgesic agents based on 6-prenylnaringenin as the T-type calcium channel blockers.
AID1711084Induction of cell cycle arrest in human A549 cells assessed as accumulation at sub G1 phase at 10 uM after 48 hrs by flow cytometric analysis (Rvb = 4.9%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells.
AID1662451Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline derivatives as novel T-type calcium channel blockers.
AID1330315Antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-stimulated Ca2+ flux up to 100 uM after 30 mins by calcium-4 dye based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID1367945Inhibition of Cav3.3 (unknown origin)2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
AID732965Drug metabolism in human liver microsomes assessed as glutathione-adduct reactive metabolite formation at 1 mg/ml after 30 mins2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor.
AID1367948Inhibition of rat Cav2.2-alpha1beta/alpha2delta/beta3 expressed in HEK293 cells assessed as decrease in calcium mobilization response to KCl after 1 hr by Fluo-4-AM dye-based FLIPR assay2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
AID1367946Inhibition of Cav1.2 (unknown origin)2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
AID12234881-Octanol-water distribution coefficient, log D of the compound at pH 7.42012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1711064Induction of cell cycle arrest in human A549 cells assessed as accumulation at sub G1 phase at 10 uM after 24 hrs by flow cytometric analysis (Rvb = 7.8%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells.
AID1662453Inhibition of human Cav3.1 expressed in tsA-201 cells by patch clamp electrophysiology2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline derivatives as novel T-type calcium channel blockers.
AID478834Inhibition of T-type calcium channel alpha1G expressed in human HEK293 cells assessed as inhibition of KCl-induced decrease in calcium level at 10 uM after 60 mins by FDSS6000 assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers.
AID319994Antagonist activity at human alpha1H T-type calcium channel expressed in HEK293 cells by patch clamp technique2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core.
AID1215394Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent dimethyl pyrroline N-oxide2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID732967Intrinsic clearance in human liver microsomes at 1 mg/ml after 45 mins2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor.
AID1207251Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1215395Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes assessed as decrease in CYP3A4-CO binding at 10 uM preincubated for 5 mins measured after 12 hrs by LC-tandem mass spectrometry analysis in presence of 1 mM NADPH2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID1594448Inhibition of Cav3.2 (unknown origin) assessed as reduction in KCl-induced increase in intracellular calcium level at 10 uM by fura-2 AM indicator based FDSS assay relative to control2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model.
AID1215390Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent N-acetyl cysteine2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID478835Inhibition of T-type calcium channel alpha1G expressed in human HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers.
AID1058668Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers.
AID82383Concentration of the compounds required for inhibition of HEK293 cells (alpha1G T-type)2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers.
AID287270Inhibition of T type calcium channel subunit alpha1G expressed in HEK293 cells assessed as effect on KCl-induced increase in intracellular calcium level at 10 uM by FDSS assay2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Lead discovery and optimization of T-type calcium channel blockers.
AID301833Selectivity for Alpha-1B N-type calcium channel over alpha-1G T-type calcium channel expressed in HEK293 cells at 10 uM2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Discovery of potent T-type calcium channel blocker.
AID1711065Induction of cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 10 uM after 24 hrs by flow cytometric analysis (Rvb = 53.1%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells.
AID681122TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1128392Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 10 uM after 48 hrs by flow cytometry (Rvb = 12.0 %)2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID681128TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID244159Selectivity for T-type and N-type [Ca2+] channels expressed in HEK293 cells at 10 uM2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers.
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID290939Displacement of [3H]dofetilide from hERG expressed in HEK293 cells by SPA2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
AID1215392Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent superoxide dismutase2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID1128358Inhibition of T-type CaV3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of calcium current by whole cell patch-clamp method2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
AID1630249Inhibition of T-type alpha1H channel (unknown origin) expressed in HEK293 cells at 10 uM by fluorescence-based HTS assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and evaluation of 6-pyrazoylamido-3N-substituted azabicyclo[3,1,0]hexane derivatives as T-type calcium channel inhibitors for treatment of neuropathic pain.
AID1215388Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent potassium cyanide2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID519606Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1215398Effect on CYP3A4 (unknown origin) apoprotein formation at 10 uM pre-incubated for 3 mins by mass spectrometry analysis in presence of 1 mM NADPH2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346688Human Cav1.2 (Voltage-gated calcium channels)2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Mibefradil block of cloned T-type calcium channels.
AID1346720Human Cav3.2 (Voltage-gated calcium channels)2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Mibefradil block of cloned T-type calcium channels.
AID1346448Human CatSper2 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm.
AID1346698Rat Cav2.3 (Voltage-gated calcium channels)2000Neuropharmacology, , Volume: 39, Issue:1
Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels.
AID1346498Human CatSper4 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm.
AID1346536Human CatSper3 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm.
AID1346462Human CatSper1 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm.
AID1346702Human Cav3.3 (Voltage-gated calcium channels)2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Mibefradil block of cloned T-type calcium channels.
AID1346724Rat Cav2.1 (Voltage-gated calcium channels)2000Neuropharmacology, , Volume: 39, Issue:1
Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels.
AID1346719Human Cav3.1 (Voltage-gated calcium channels)2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Mibefradil block of cloned T-type calcium channels.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1802150TREK1 Assay from Article 10.1111/cbdd.12810: \\Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.\\2016Chemical biology & drug design, Dec, Volume: 88, Issue:6
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (647)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.31)18.7374
1990's231 (35.70)18.2507
2000's243 (37.56)29.6817
2010's148 (22.87)24.3611
2020's23 (3.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.99 (24.57)
Research Supply Index6.60 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index57.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials69 (10.34%)5.53%
Reviews42 (6.30%)6.00%
Case Studies9 (1.35%)4.05%
Observational0 (0.00%)0.25%
Other547 (82.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride With Hypofractionated Re-Irradiation Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (GBM) [NCT02202993]Phase 118 participants (Actual)Interventional2014-08-31Completed
A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment [NCT01480050]Phase 128 participants (Actual)Interventional2012-05-31Completed
A Study of the Pharmacokinetic and Safety Profile of QID Dosing of Mibefradil in Normal Human Volunteers [NCT01550458]Phase 130 participants (Actual)Interventional2012-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]